Voss, Martin H. http://orcid.org/0000-0003-0551-5807
Gordon, Michael S.
Mita, Monica
Rini, Brian
Makker, Vicky
Macarulla, Teresa
Smith, David C.
Cervantes, Andrés
Puzanov, Igor
Pili, Roberto
Wang, Ding
Jalal, Shadia
Pant, Shubham
Patel, Manish R.
Neuwirth, Rachel l.
Enke, Aaron
Shou, Yaping
Sedarati, Farhad
Faller, Douglas V.
Burris, Howard A. III
Funding for this research was provided by:
Millennium Pharmaceuticals Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
Article History
Received: 13 December 2019
Revised: 17 July 2020
Accepted: 13 August 2020
First Online: 11 September 2020
Ethics approval and consent to participate
: The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. Institutional review boards (listed in the Supplementary Information) approved all aspects of the study. All participants provided written informed consent.
: The datasets, including the redacted study protocol, redacted statistical analysis plan and individual participants data supporting the results reported in this article, will be made available within three months from initial request, to researchers who provide a methodologically sound proposal. The data will be provided after its de-identification, in compliance with applicable privacy laws, data protection and requirements for consent and anonymisation.
: M.H.V. has received honoraria from Novartis and consultancy fees from Alexion Pharmaceuticals, Bayer, Calithera Biosciences, Corvus Pharmaceuticals, Exelixis, Eisai, GlaxoSmithKline, Natera, Novartis, Ontarget therapeutics and Pfizer. He has received research funding from Bristol-Myers Squibb, Genentech and Pfizer, and travel grants from Takeda and Eisai. M.S.G. has ownership of stock/shares with Medelis, CARE Mission and Beckon Call, and received consulting fees from Agenus, Deciphera and Salarius. B.R. is an advisor for and has received consultancy fees and research funding from Pfizer, Merck, Bristol-Myers Squibb and Roche. He has also received researching funding from AstraZeneca and Peloton. V.M. is an advisor for Eisai, Merck and Karyopharm, and has received honoraria from Eisai and Merck. He has received research funding from Eisai, Merck, Lilly, Karyopharm, Bristol-Myers Squibb, AstraZeneca, Takeda and Genentech. T.M. is an advisor for Roche, Amgen, Novartis, Sanofi, Shire, Incyte, Celgene and Baxter, and is a speaker for Celgene, Shire, Sanofi, Amgen and Servier. She has received research funding from Beigene, Novartis and Celgene. D.C.S. has received research funding from Agensys, Bayer, Exelixis, Incyte, Lilly, MedImmune, Novartis, OncoMed, Seattle Genetics, Bristol-Myers Squibb/Medarex, Essa, Genentech, Medivation/Astellas, Merck, Astellas and Takeda. A.C. is an advisor for Merck Serono, Roche, Beigene, Bayer, Servier, Lilly, Novartis, Takeda, Astelas, Pierre Fabre, Amgen and Foundation Medicine. He has received grants from Merck Serono and Roche, and research funding from Genentech, Merck Serono, Roche, Beigene, Bayer, Servier, Lilly, Novartis, Takeda, Astelas, Fibrogen, Amcure, Sierra Oncology, AstraZeneca, MedImmune, Bristol-Myers Squibb and MSD. I.P. is an advisor for and has received honoraria and consultancy fees from Amgen. He has received research funding from Nektar, Amgen, Rgenix and ADC. S.J. has received grants from AstraZeneca, Tesaro and Astex. S.P. has received honoraria from UD Pharma and Tyme Inc. R.I.N., A.E., Y.S., F.S. and D.V.F. are employed by Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Co. Ltd. H.B. is an advisor for Mersana, AstraZeneca, FORMA Therapeutics, Janssen, Novartis, Roche/Genentech, MedImmune, Bristol-Myers Squibb, Celgene, Incyte, Boehringer Ingelheim, Eisai and Tolero Pharmaceuticals. He has received research funding from Roche/Genentech, Bristol-Myers Squibb, Incyte, AstraZeneca, MedImmune, Macrogenics, Novartis, Boehringer Ingelheim, Lilly, Seattle Genetics, Merck, Celgene, Agios, Jounce Therapeutics, Morderna Therapeutics, CytomX Therapeutics, GlaxoSmithKline, Verastem, Tesaro, Immunocore, Takeda, BioMed Valley Discoveries, TG Therapeutics, Loxo, Vertex, eFFECTOR Therapeutics, Janssen, Gilead Sciences, BioAtla, CicioMed, Harpoon Therapeutics, Jiangsu Hengrui Medicine, Arch, Kyocera, Arvinas and Revolution Medicines. He has provided expert testimony for Novartis. All remaining authors have declared no conflicts of interest.
: This study was supported by Millennium Pharmaceuticals Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. NIH/NCI Cancer Center Support Grant (Memorial Sloan Kettering Cancer Center, P30 CA008748).